Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nidal Al-Huniti

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Journal of Clinical Pharmacology|March 9, 2016
Reply to: Letter to the Editor "Effect of Quinidine, a Strong P-Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol"Nidal Al-Huniti
Clinical Pharmacology in Drug Development|May 3, 2019
Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline FosamilJianguo Li, Shampa Das, Diansong Zhou, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 21, 2018
Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methodsJingtao Lu, Jianguo Li, Gabriel Helmlinger, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2018
Simplified Aztreonam Dosing in Patients with End-Stage Renal Disease: Results of a Monte Carlo SimulationAlan E Gross, Hongmei Xu, Diansong Zhou, et al.
Journal of Clinical Pharmacology|May 16, 2015
Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorderDiansong Zhou, Khanh H Bui, Jianguo Li, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 11, 2020
Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non-Small Cell Lung CancerMario Nagase, Sergey Aksenov, Hong Yan, et al.
British Journal of Clinical Pharmacology|February 19, 2017
Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancerJianguo Li, Nidal Al-Huniti, Anja Henningsson, et al.
Journal of Clinical Pharmacology|August 18, 2016
Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation AnalysisHongmei Xu, Wangda Zhou, Diansong Zhou, et al.
Primary Care Respiratory Journal : Journal of the General Practice Airways Group|March 24, 2007
Clinical and therapeutic variables influencing hospitalisation for bronchiolitis in a community-based paediatric group practiceBaha Al-Shawwa, Nidal Al-Huniti, Miles Weinberger, et al.
British Journal of Clinical Pharmacology|December 24, 2017
Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancerNidal Al-Huniti, Klas Petersson, Weifeng Tang, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Journal of Clinical Pharmacology|March 9, 2016
Reply to: Letter to the Editor "Effect of Quinidine, a Strong P-Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol"Nidal Al-Huniti
Clinical Pharmacology in Drug Development|May 3, 2019
Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline FosamilJianguo Li, Shampa Das, Diansong Zhou, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 21, 2018
Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methodsJingtao Lu, Jianguo Li, Gabriel Helmlinger, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2018
Simplified Aztreonam Dosing in Patients with End-Stage Renal Disease: Results of a Monte Carlo SimulationAlan E Gross, Hongmei Xu, Diansong Zhou, et al.
Journal of Clinical Pharmacology|May 16, 2015
Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorderDiansong Zhou, Khanh H Bui, Jianguo Li, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 11, 2020
Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non-Small Cell Lung CancerMario Nagase, Sergey Aksenov, Hong Yan, et al.
British Journal of Clinical Pharmacology|February 19, 2017
Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancerJianguo Li, Nidal Al-Huniti, Anja Henningsson, et al.
Journal of Clinical Pharmacology|August 18, 2016
Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation AnalysisHongmei Xu, Wangda Zhou, Diansong Zhou, et al.
Primary Care Respiratory Journal : Journal of the General Practice Airways Group|March 24, 2007
Clinical and therapeutic variables influencing hospitalisation for bronchiolitis in a community-based paediatric group practiceBaha Al-Shawwa, Nidal Al-Huniti, Miles Weinberger, et al.
British Journal of Clinical Pharmacology|December 24, 2017
Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancerNidal Al-Huniti, Klas Petersson, Weifeng Tang, et al.
Pageof 6